0001127602-23-006642.txt : 20230223 0001127602-23-006642.hdr.sgml : 20230223 20230223095427 ACCESSION NUMBER: 0001127602-23-006642 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230221 FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kirchgraber Paul R CENTRAL INDEX KEY: 0001791393 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11353 FILM NUMBER: 23656939 MAIL ADDRESS: STREET 1: 531 SOUTH SPRING STREET CITY: BURLINGTON STATE: NC ZIP: 27215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LABORATORY CORP OF AMERICA HOLDINGS CENTRAL INDEX KEY: 0000920148 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 133757370 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 358 S MAIN ST CITY: BURLINGTON STATE: NC ZIP: 27215 BUSINESS PHONE: 3362291127 MAIL ADDRESS: STREET 1: 358 S MAIN ST CITY: BURLINGTON STATE: NC ZIP: 27215 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL HEALTH LABORATORIES HOLDINGS INC DATE OF NAME CHANGE: 19940314 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2023-02-21 0000920148 LABORATORY CORP OF AMERICA HOLDINGS LH 0001791393 Kirchgraber Paul R 531 SOUTH SPRING STREET BURLINGTON NC 27215 1 CEO, Covance Drug Development Common Stock 2023-02-21 4 M 0 3000 182.51 A 17069 D Common Stock 2023-02-21 4 S 0 8000 250.5844 D 9069 D Non-qualified Stock Options 182.51 2023-02-21 4 M 0 3000 0 D 2021-02-04 2030-02-03 Common Stock 3000 4300 D The price of $250.5844 per share represents a weighted average of sales prices ranging from $250.44 to $250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. The option vested in three equal annual installments beginning on the date reflected in this column. /s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber 2023-02-23